VLCAD stands for very long-chain acyl-CoA dehydrogenase deficiency, a rare inherited condition where a baby’s body cannot properly break down certain fats for energy. It affects roughly 1 in 30,000 to 1 in 400,000 births depending on the population, and most parents first hear about it through their newborn’s routine heel-prick screening test. VLCAD is manageable with early detection and dietary changes, but it requires lifelong monitoring.
How VLCAD Affects Energy Production
Your body normally converts stored fat into energy through a process called beta-oxidation, which takes place inside the mitochondria of your cells. This process works like peeling layers off a chain: with each cycle, two carbon atoms are clipped from a fatty acid, releasing energy along the way. The VLCAD enzyme handles the first step of this process specifically for long-chain fats (those with 14 to 20 carbon atoms), which are among the most common fats in breast milk, formula, and body stores.
When a baby has VLCAD deficiency, this enzyme is missing or not working well enough. Long-chain fats pile up instead of being converted to fuel. This creates two problems at once: the body loses access to a major energy source, and the accumulated fats can become toxic to organs like the heart, liver, and muscles. The condition is particularly dangerous during fasting, illness, or any situation where the body would normally rely on burning fat reserves.
Three Forms Based on Severity
VLCAD deficiency exists on a spectrum, and clinicians recognize three forms based on when symptoms first appear and which organs are involved.
The early-onset (severe) form shows up in the first months of life. It is the most serious type. Babies may develop life-threatening heart problems, including thickening of the heart muscle (cardiomyopathy) and dangerous rhythm disturbances. Lethargy, muscle weakness, liver abnormalities, and dangerously low blood sugar are common. A combination of heart, liver, and muscle problems alongside low blood sugar with absent ketones is a hallmark pattern of fatty acid oxidation disorders like VLCAD.
The childhood-onset form typically appears later in infancy or early childhood. It primarily affects the liver, causing enlargement and episodes of low blood sugar, especially after periods without eating. Heart involvement is less common, though muscle weakness can occur.
The adult-onset form is the mildest. It usually surfaces in adolescence or adulthood as exercise-triggered muscle pain and episodes of muscle breakdown (rhabdomyolysis), which can turn urine red or brown.
The form a child develops generally corresponds to how much working enzyme they have. Babies with less than about 35% of normal enzyme activity tend to have more severe disease.
How VLCAD Is Inherited
VLCAD follows an autosomal recessive pattern, meaning a baby must inherit one faulty copy of the ACADVL gene from each parent to be affected. Parents who each carry one copy typically have no symptoms and often have no idea they’re carriers until their child’s screening comes back positive.
Researchers have catalogued over 450 different mutations in the ACADVL gene, and the most common ones vary by ancestry. European and American populations most frequently carry one particular variant, while different variants predominate in Middle Eastern and East Asian populations. This genetic diversity is one reason severity varies so widely from one child to the next.
Newborn Screening and Diagnosis
In the United States and many other countries, VLCAD is part of the standard newborn screening panel. The test measures levels of a specific fat marker called C14:1 acylcarnitine in a drop of blood taken from the baby’s heel. Elevated C14:1, sometimes along with other long-chain markers, triggers a positive screen.
A positive newborn screen is not a diagnosis. It means further testing is needed. The next steps typically include a repeat blood test to look at the full acylcarnitine profile and genetic testing to identify mutations in the ACADVL gene. In cases where genetic results are inconclusive, doctors can measure VLCAD enzyme activity directly using a skin cell sample or blood cells. Confirmed patients with VLCAD deficiency consistently show less than 35% of normal enzyme activity in these tests.
Because expanded newborn screening catches many mild cases that might never have caused symptoms on their own, some families will learn their baby has a biochemical abnormality but may never develop clinical disease. This can be confusing, but close follow-up with a metabolic specialist helps clarify the picture over time.
Dietary Management in Infants
The cornerstone of VLCAD management is controlling which types of fat your baby eats and making sure they never go too long without food. Since the body can’t process long-chain fats efficiently, the goal is to limit those fats and replace them with medium-chain triglycerides (MCT), which bypass the broken enzyme and use a different pathway for energy.
For infants with severe disease, this means using a specialized low-fat formula where total fat provides roughly 13% to 39% of calories, supplemented with MCT oil to add another 15% to 18% of calories. Babies with moderate VLCAD deficiency who are asymptomatic can often breastfeed, sometimes supplemented with a high-MCT medical formula. A metabolic dietitian will tailor the specific ratio based on your baby’s severity and growth needs.
Preventing long fasts is equally critical. Expert panels generally recommend feeding every 3 to 4 hours for the first four months of life. Some clinicians use a weight-based rule: one hour of fasting per kilogram of body weight, up to a maximum of about 8 hours at 8 kilograms. By 12 months, many children can safely go up to 12 hours between meals. During illness, these intervals are often cut in half because a sick body burns through glucose faster and turns to fat stores sooner.
What Happens During a Metabolic Crisis
A metabolic crisis occurs when the body runs out of readily available glucose and tries to burn fat it cannot process. This can be triggered by a stomach bug, fever, skipped meals, or any stress that increases energy demand. Warning signs include unusual sleepiness, poor feeding, vomiting, and rapid breathing. In severe cases, the heart can become dangerously affected.
The immediate treatment is providing glucose quickly to stop the body from relying on fat. For mild episodes at home, this may mean offering frequent carbohydrate-rich fluids. For more serious episodes, a trip to the emergency room is necessary. Families of children with VLCAD typically carry an emergency letter from their metabolic team explaining the condition and the need for prompt glucose support, since most ER physicians rarely encounter this disorder.
Long-Term Outlook
The prognosis for VLCAD deficiency has improved dramatically since newborn screening became widespread. Babies identified before their first crisis and started on appropriate dietary management do significantly better than those diagnosed only after a severe episode. Children with the milder childhood-onset form generally do well with dietary precautions and illness management plans.
The early-onset severe form carries the highest risk, particularly for heart complications in the first year of life. However, many children with severe VLCAD who survive infancy see their cardiac function stabilize or improve with treatment. The condition does not go away, but the heart’s vulnerability often decreases as children grow, partly because older children can eat more frequently on their own and have larger glycogen stores to draw on between meals.
VLCAD is a lifelong condition that requires ongoing attention to diet, fasting avoidance, and illness planning. Most children attend regular school, participate in age-appropriate activities, and lead full lives, particularly when their families and medical teams work together to prevent crises before they start.